Y-mAbs Therapeutics, Inc. has entered a development, manufacturing and supply agreement with SpectronRx in South Bend, IN, to secure access to clinical and commercial scale radiolabeling capacity for omburtamab.    Under the terms of the agreement, SpectronRx has agreed to establish a manufacturing unit designated for Y-mAbs within its existing facilities, at which both clinical and commercial supply of radiolabeled omburtamab can be produced.   Omburtamab is in a pivotal Phase II trial for the ...